Adverse oral reactions associated with the COX-2 inhibitor rofecoxib

Oral Diseases

Volumn 10, Issue 6, 2004, Pages 401-403

  Bagán, José V ^a,b   Thongprasom, K ^c   Scully, C ^d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cox; Oral manifestations; Rofecoxib; Ulcers

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; FLUOCINOLONE ACETONIDE; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CASE REPORT; EROSION; FEMALE; HUMAN; MOUTH DISEASE; MOUTH MUCOSA; MOUTH ULCER; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; LACTONES; LICHENOID ERUPTIONS; ORAL ULCER; SULFONES;

EID: 9444232778     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2004.01024.x     Document Type: Article

References (23)

1. Ahuja N, Singh A, Singh B (2003). Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 55: 859-894.
2. Arboleya LR, de Figuera E, Soledad Garcia M, Aragon B (2003). VICOXX Study Group. Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. Curr Med Res Opin 19: 288-297.
3. Chang DJ, Fricke JR, Bird SR, Bohidar NR, Dobbins TW, Geba GP (2001). Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther 23: 1446-1455.
4. Chang DJ, Desjardins PJ, Chen E et al. (2002). Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial. Clin Ther 24: 490-503.
5. Dicker AP (2003). COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy. Reports from a Symposium Held in Conjunction with the Radiation Therapy Oncology Group, June 2001 Meeting. Am J Clin Oncol 26: S46-S47.
6. Ferguson MM, Wiesenfeld D, MacDonald DG (1984). Oral mucosal lichenoid eruption due to fenclofenac. J Oral Med 39: 39-40.
7. Gopikrishna V, Parameswaran A (2003). Effectiveness of prophylactic use of rofecoxib in comparison with ibuprofen on postendodontic pain. J Endod 29: 62-64.
8. Hamburger J, Potts AJ (1983). Non-steroidal anti-inflammatory drugs and oral lichenoid reactions. Br Med J (Clin Res Ed) 287: 1258.
9. Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J (2003). Rofecoxib Rheumatoid Arthritis Endoscopy Study Group. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 52: 820-826.
10. Healy CM, Thornhill MH (1995). An association between recurrent oro-genital ulceration and nonsteroidal antiinflammatory drugs. J Oral Pathol Med 24: 46-48.
11. Hunt RH (2003). Motion-Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments for the motion. Can J Gastroenterol 17: 339-341.
12. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D (2003). Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52: 1265-1270.
13. Madinier I, Berry N, Chichmanian RM (2000). Drug-induced oral ulcerations. Ann Med Interne (Paris) 151: 248-254.
14. Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ (1999). Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator- controlled clinical trial. Clin Ther 21: 1653-1663.
15. Malmstrom K, Fricke JR, Kotey P, Kress B, Morrison B (2002). A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator- controlled, parallel-group, single-dose study using the dental impaction pain model. Clin Ther 24: 1549-1560.
16. Matheson AJ, Figgitt DP (2001). Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 61: 833-865.
17. McCartan BE, McCreary CE (1997). Oral lichenoid drug eruptions. Oral Dis 3: 58-63.
18. Moore PA, Hersh EV (2001). Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc 132: 451-456.
19. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B (1999). Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 21: 943-953.
20. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959.
21. Quiralte J, Saenz de San Pedro B, Florido JJ (2002). Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 89: 63-66.
22. Siegel MA, Balciunas BA (1991). Medication can induce severe ulcerations. J Am Dent Assoc 122: 75-77.
23. Thompson DF, Skehill PA (1994). Drug-induced lichenplanus. Pharmacotherapy 14: 561-571.